Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM THIOSULFATE vs FINGOLIMOD HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
FDA-approved: Acute cyanide poisoning (in combination with sodium nitrite),Off-label: Reduction of nephrotoxicity from cisplatin chemotherapy,Off-label: Calciphylaxis (calcium uremic arteriolopathy),Off-label: Treatment of extravasation of vesicant drugs
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.
0.5 mg orally once daily
Terminal elimination half-life: 0.65 hours (IV in cyanide poisoning); context: rapid redistribution and excretion, requiring repeated doses.
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Sodium thiosulfate is metabolized via the enzyme rhodanese (in liver and other tissues) to thiocyanate, which is then excreted renally. It also undergoes oxidation to sulfate.
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Renal: >90% unchanged; minor biliary/fecal.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
<5%; primarily albumin.
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
0.2-0.3 L/kg; indicates primarily extracellular distribution.
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
Oral: approximately 0% (poorly absorbed, degraded in stomach); IV: 100%.
Oral bioavailability is approximately 93% (range 80–100%).
No dose adjustment required for GFR >30 m L/min; for GFR ≤30 m L/min, consider reducing dose by 50% or extending interval to every 12 hours due to possible thiosulfate accumulation.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
No specific recommendations for Child-Pugh; use with caution in severe hepatic impairment due to potential metabolic and elimination effects.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
For cyanide poisoning: 412.5 mg/kg (1.65 m L/kg of 25% solution) intravenously over 10 minutes; for methemoglobinemia: 1 mg/kg intravenously over 10 minutes.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
No specific dose adjustments; monitor renal function and volume status due to sodium load and potential reduced clearance.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
None.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
Hypotension and increased anion gap metabolic acidosis (especially with high doses or rapid infusion),Hypocalcemia due to calcium chelation; monitor calcium levels,Thiocyanate accumulation, particularly in renal impairment; can lead to toxicity (e.g., nausea, disorientation, psychosis, muscle cramps),Hydration status should be monitored to avoid volume overload,Hypersensitivity reactions may occur
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
Known hypersensitivity to sodium thiosulfate or any component,Relative: Severe renal impairment (risk of thiocyanate toxicity)
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
No known food interactions. Maintain adequate hydration unless contraindicated by renal status.
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide poisoning during pregnancy when benefit outweighs risk.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
Sodium thiosulfate is excreted into breast milk in small amounts; M/P ratio is not established. It is considered compatible with breastfeeding, but caution is advised due to limited data.
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
No dosage adjustment is recommended for pregnancy. Pharmacokinetic changes in pregnancy are not well studied; standard weight-based dosing for cyanide poisoning should be used.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
Sodium thiosulfate is used as an antidote for cyanide poisoning and for calciphylaxis. In cyanide poisoning, administer IV with sodium nitrite; monitor for hypotension and methemoglobinemia. For calciphylaxis, use after hemodialysis to prevent hypernatremia. Can cause prolonged QT interval, so monitor ECG. Do not mix with other drugs in IV line; incompatible with cisplatin.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
This medication is given intravenously to treat cyanide poisoning or a skin condition called calciphylaxis.,You may experience side effects such as nausea, vomiting, headache, or a metallic taste.,Your blood pressure, heart rhythm, and blood levels will be monitored during treatment.,Tell your doctor if you have heart problems, kidney disease, or low sodium levels.,Do not drink alcohol while on this medication.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM THIOSULFATE vs FINGOLIMOD HYDROCHLORIDE, answered by our medical review team.
SODIUM THIOSULFATE is a Cyanide Antidote that works by Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.. FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM THIOSULFATE and FINGOLIMOD HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM THIOSULFATE is: 12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.. The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM THIOSULFATE and FINGOLIMOD HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM THIOSULFATE is classified as Category C. Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide . FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.